173 related articles for article (PubMed ID: 31187190)
1. Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis.
Berger KI; Kanters S; Jansen JP; Stewart A; Sparks S; Haack KA; Bolzani A; Siliman G; Hamed A
J Neurol; 2019 Sep; 266(9):2312-2321. PubMed ID: 31187190
[TBL] [Abstract][Full Text] [Related]
2. Positive association between physical outcomes and patient-reported outcomes in late-onset Pompe disease: a cross sectional study.
Yuan M; Andrinopoulou ER; Kruijshaar ME; Lika A; Harlaar L; van der Ploeg AT; Rizopoulos D; van der Beek NAME
Orphanet J Rare Dis; 2020 Sep; 15(1):232. PubMed ID: 32883321
[TBL] [Abstract][Full Text] [Related]
3. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.
Schoser B; Stewart A; Kanters S; Hamed A; Jansen J; Chan K; Karamouzian M; Toscano A
J Neurol; 2017 Apr; 264(4):621-630. PubMed ID: 27372449
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of short- and long-term inspiratory muscle training in late-onset Pompe disease (LOPD): a pilot study.
Wenninger S; Greckl E; Babačić H; Stahl K; Schoser B
J Neurol; 2019 Jan; 266(1):133-147. PubMed ID: 30430231
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity, forced vital capacity) predict ventilator use in late-onset Pompe disease.
Johnson EM; Roberts M; Mozaffar T; Young P; Quartel A; Berger KI
Neuromuscul Disord; 2016 Feb; 26(2):136-45. PubMed ID: 26794303
[TBL] [Abstract][Full Text] [Related]
6. The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?
Lachmann R; Schoser B
Orphanet J Rare Dis; 2013 Oct; 8():160. PubMed ID: 24119230
[TBL] [Abstract][Full Text] [Related]
7. Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function.
Gaeta M; Barca E; Ruggeri P; Minutoli F; Rodolico C; Mazziotti S; Milardi D; Musumeci O; Toscano A
Mol Genet Metab; 2013 Nov; 110(3):290-6. PubMed ID: 23916420
[TBL] [Abstract][Full Text] [Related]
8. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease.
Harlaar L; Hogrel JY; Perniconi B; Kruijshaar ME; Rizopoulos D; Taouagh N; Canal A; Brusse E; van Doorn PA; van der Ploeg AT; Laforêt P; van der Beek NAME
Neurology; 2019 Nov; 93(19):e1756-e1767. PubMed ID: 31619483
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis.
Sarah B; Giovanna B; Emanuela K; Nadi N; Josè V; Alberto P
J Neurol; 2022 Feb; 269(2):733-741. PubMed ID: 33851281
[TBL] [Abstract][Full Text] [Related]
10. Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.
Vanherpe P; Fieuws S; D'Hondt A; Bleyenheuft C; Demaerel P; De Bleecker J; Van den Bergh P; Baets J; Remiche G; Verhoeven K; Delstanche S; Toussaint M; Buyse B; Van Damme P; Depuydt CE; Claeys KG
Orphanet J Rare Dis; 2020 Apr; 15(1):83. PubMed ID: 32248831
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.
Kishnani PS; Diaz-Manera J; Toscano A; Clemens PR; Ladha S; Berger KI; Kushlaf H; Straub V; Carvalho G; Mozaffar T; Roberts M; Attarian S; Chien YH; Choi YC; Day JW; Erdem-Ozdamar S; Illarioshkin S; Goker-Alpan O; Kostera-Pruszczyk A; van der Ploeg AT; An Haack K; Huynh-Ba O; Tammireddy S; Thibault N; Zhou T; Dimachkie MM; Schoser B;
JAMA Neurol; 2023 Jun; 80(6):558-567. PubMed ID: 37036722
[TBL] [Abstract][Full Text] [Related]
12. Utility of maximum inspiratory and expiratory pressures as a screening method for respiratory insufficiency in slowly progressive neuromuscular disorders.
Wenninger S; Stahl K; Wirner C; Einvag K; Thiele S; Walter MC; Schoser B
Neuromuscul Disord; 2020 Aug; 30(8):640-648. PubMed ID: 32690350
[TBL] [Abstract][Full Text] [Related]
13. Pompe disease in Austria: clinical, genetic and epidemiological aspects.
Löscher WN; Huemer M; Stulnig TM; Simschitz P; Iglseder S; Eggers C; Moser H; Möslinger D; Freilinger M; Lagler F; Grinzinger S; Reichhardt M; Bittner RE; Schmidt WM; Lex U; Brunner-Krainz M; Quasthoff S; Wanschitz JV
J Neurol; 2018 Jan; 265(1):159-164. PubMed ID: 29181627
[TBL] [Abstract][Full Text] [Related]
14. Ultrasound assessment of diaphragm function in patients with late-onset Pompe disease.
Ruggeri P; Lo Monaco L; Musumeci O; Tavilla G; Gaeta M; Caramori G; Toscano A
Neurol Sci; 2020 Aug; 41(8):2175-2184. PubMed ID: 32162165
[TBL] [Abstract][Full Text] [Related]
15. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start.
Stockton DW; Kishnani P; van der Ploeg A; Llerena J; Boentert M; Roberts M; Byrne BJ; Araujo R; Maruti SS; Thibault N; Verhulst K; Berger KI
J Neurol; 2020 Oct; 267(10):3038-3053. PubMed ID: 32524257
[TBL] [Abstract][Full Text] [Related]
16. Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS
Kishnani PS; Shohet S; Raza S; Hummel N; Castelli JP; Sitaraman Das S; Jiang H; Kopiec A; Keyzor I; Hahn A
J Patient Rep Outcomes; 2024 Jan; 8(1):13. PubMed ID: 38294575
[TBL] [Abstract][Full Text] [Related]
17. Role of the cardio-pulmonary exercise test and six-minute walking test in the evaluation of exercise performance in patients with late-onset Pompe disease.
Crescimanno G; Modica R; Lo Mauro R; Musumeci O; Toscano A; Marrone O
Neuromuscul Disord; 2015 Jul; 25(7):542-7. PubMed ID: 25908581
[TBL] [Abstract][Full Text] [Related]
18. Progression from respiratory dysfunction to failure in late-onset Pompe disease.
Berger KI; Chan Y; Rom WN; Oppenheimer BW; Goldring RM
Neuromuscul Disord; 2016 Aug; 26(8):481-9. PubMed ID: 27297666
[TBL] [Abstract][Full Text] [Related]
19. Respiratory muscle training (RMT) in late-onset Pompe disease (LOPD): Effects of training and detraining.
Jones HN; Crisp KD; Robey RR; Case LE; Kravitz RM; Kishnani PS
Mol Genet Metab; 2016 Feb; 117(2):120-8. PubMed ID: 26381077
[TBL] [Abstract][Full Text] [Related]
20. Respiratory manifestations in late-onset Pompe disease: a case series conducted in Brazil.
Sixel BS; Silva LD; Cavalcanti NC; Penque GM; Lisboa S; Horovitz DD; Llerena JC
J Bras Pneumol; 2017; 43(1):54-59. PubMed ID: 28380188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
